AJDOVŠCINA, Slovenia—BIA Separations, a leading biochromatography development and manufacturing company, announced recently the expansion of its services with the opening of a new upstream processing (USP) laboratory.
The investment in the new facility comes in response to customer demand for services that optimize the critical interface between upstream and downstream processing for the robust and scalable production of complex molecules and biologics, such as viral vectors, phages and exosomes. The new USP facility will reportedly ensure biopharmaceutical manufacturing processing is developed and delivered to customers in an integrated way, with full coordination of critical steps, such as upstream choice of cell line; source and supply of materials; bioreactor processing parameters and the consequential impact on downstream product purification; formulation; and stability profiles.
“This month, BIA Separations celebrates our 20th Anniversary and we are delighted to mark it with the opening of this new USP facility,” Aleš Štrancar, CEO of BIA Separations, said in September as part of the announcement. “Alongside our many years’ experience and expertise in understanding and controlling bioprocesses, we now have the capability to manage the interface between upstream and downstream processes, which is key for complex biologics production.”
BIA Separations is a developer and manufacturer of Convective Interaction Media monolithic chromatographic columns for production, purification and analytics of large biomolecules; in addition, the company aims to provide unique in-process control tools to better understand and control the bioprocesses.
